EUCTR2020-005435-75-DK进行中（未招募）1 期
Protocol Title: Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 3,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female
- •- Age above or equal to 18 years at the time of signing informed consent
- •- a) BMI greater than or equal to 30.0 kg/m^2 or b) BMI greater than or equal to 27.0 kg/m^2 with the presence of at least one obesity related complication including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3128
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 272
排除标准
- •Glycaemia related:
- •-HbA1c greater than or equal to 6.5 % (48 mmol/mol) as measured by the central laboratory at screening
- •-History of type 1 or type 2 diabetes mellitus
研究者
相似试验
招募中
1 期
REDEFINE 1: A research study to see how well CagriSema helps people losing weight in people who have a body weight above the healthy rangeObesity, OverweightMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 24.1Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2020-005435-75-BGovo Nordisk A/S3,400
进行中（未招募）
1 期
REDEFINE 1: A research study to see how well CagriSema helps people losing weight in people who have a body weight above the healthy rangeObesity, OverweightMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 24.1Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2020-005435-75-FRovo Nordisk A/S3,400
进行中（未招募）
1 期
A research study to see how well CagriSema helps people losing weight in people who have a body weight above the healthy rangeObesity, OverweightMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 24.1Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2020-005435-75-PLovo Nordisk A/S3,400
进行中（未招募）
1 期
REDEFINE 1: A research study to see how well CagriSema helps people losing weight in people who have a body weight above the healthy rangeObesity, OverweightMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 24.1Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2020-005435-75-FIovo Nordisk A/S3,400
招募中
3 期
REIMAGINE 2: A research study to see how well CagriSema compared to semaglutide, cagrilintide and placebo lowers blood sugar and body weight in people with type 2 diabetes treated with metformin with or without an SGLT2 inhibitorType 2 diabetesJPRN-jRCT2031230369Hiroko Nishida2,700